Latest Breaking News On - Chief medical officer dmitri bobilev - Page 1 : comparemela.com

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
smdailyjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from smdailyjournal.com Daily Mail and Mail on Sunday newspapers.

United statesLuke nordquistAmanda crayDmitri bobilevNiowave incFusion pharmaceuticalsDrug administrationFusion pharmaceuticals incInvestor relations corporate communicationsExchange commissionChief medical officer dmitri bobilevChief executiveGood manufacturing practicePrivate securities litigation reform actInvestor relations

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesDmitri bobilevAmanda crayLuke nordquistInvestor relations corporate communicationsFusion pharmaceuticalsDrug administrationFusion pharmaceuticals incExchange commissionNiowave incChief medical officer dmitri bobilevChief executiveGood manufacturing practicePrivate securities litigation reform actInvestor relations

Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in this Arm is Currently Enrolling Data to be Presented .

United statesDmitri bobilevJohn valliantNeeta pandit taskarAmanda crayNiowave incMemorial sloan kettering cancer centerSociety of nuclear medicineInvestor relations corporate communicationsFusion pharmaceuticals incFusion pharmaceuticalsPreliminary clinical dataHot dosing regimen demonstrate potentialImprove therapeutic indexHot dosing regimenNuclear medicine